Anti-14-3-3 sigma/SFN antibody [EPR5873(2)] - BSA and Azide free,Abcam,AB251175
ab251175 is the carrier-free version of ab193667 . Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies . Conjugation ready Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications. Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold. Compatibility This product is compatible with the Maxpar ® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar ® is a trademark of Fluidigm Canada Inc.
Host
Rabbit
Reactivity
Human
Application
IHC-P, WB
Platform ID
BAB141076602
Abcam
Contact
Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215
Email:
Specifications
Scientific Background
Target data Adapter protein implicated in the regulation of a large spectrum of both general and specialized signaling pathways (PubMed : 15731107, PubMed : 22634725, PubMed : 28202711, PubMed : 37797010). Binds to a large number of partners, usually by recognition of a phosphoserine or phosphothreonine motif (PubMed : 15731107, PubMed : 22634725, PubMed : 28202711, PubMed : 37797010). Binding generally results in the modulation of the activity of the binding partner (PubMed : 15731107, PubMed : 22634725, PubMed : 28202711, PubMed : 37797010). Promotes cytosolic retention of GBP1 GTPase by binding to phosphorylated GBP1, thereby inhibiting the innate immune response (PubMed : 37797010). Also acts as a TP53/p53-regulated inhibitor of G2/M progression (PubMed : 9659898). When bound to KRT17, regulates protein synthesis and epithelial cell growth by stimulating Akt/mTOR pathway (By similarity). Acts to maintain desmosome cell junction adhesion in epithelial cells via interacting with and sequestering PKP3 to the cytoplasm, thereby restricting its translocation to existing desmosome structures and therefore maintaining desmosome protein homeostasis (PubMed : 24124604). Also acts to facilitate PKP3 exchange at desmosome plaques, thereby maintaining keratinocyte intercellular adhesion (PubMed : 29678907). May also regulate MDM2 autoubiquitination and degradation and thereby activate p53/TP53 (PubMed : 18382127). See full target information SFN
Category Paths
- Products>Primary Antibodies>IHC Antibodies
- Products>Primary Antibodies>Recombinant Antibodies
Please provide the required information below so that we can quickly source your products.